1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval

1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2018-10, Vol.29 (suppl_8)
Hauptverfasser: Borrell Puy, M, Molto Valiente, C, Vokinger, K, Hwang, T, Ocana Fernandez, A, Templeton, A J, Seruga, B, Gich Saladich, I, Barnadas, A, Amir, E, Tibau, A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue suppl_8
container_start_page
container_title Annals of oncology
container_volume 29
creator Borrell Puy, M
Molto Valiente, C
Vokinger, K
Hwang, T
Ocana Fernandez, A
Templeton, A J
Seruga, B
Gich Saladich, I
Barnadas, A
Amir, E
Tibau, A
description
doi_str_mv 10.1093/annonc/mdy297.007
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdy297_007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy297.007</oup_id><sourcerecordid>10.1093/annonc/mdy297.007</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdy297_0073</originalsourceid><addsrcrecordid>eNqVkElPwzAQhcMmUZYfwG2ORaKt03Qhx6iLuERCAs6Ra0-CIR0bL5X673FoxYkLp5Fmvvfe6CXJXcqGKcuzESfSJEZbuR_n8yFj89Okl05n-eCRTdLzpMfycTaYT7PJZXLl3AdjbJaP897JWYSy52XJG1I-SARdg2gVKcFb2CBhrTwoAm8Vbx24YIy2XlEDby-w1loCJwlLGxoo5DbqnLfcK03QXy-Le-BCYItxhZE0xupd9O0X3SXqVsFqg5ygRKmEInRQNEhiD_1VGRmhSarOLYq23H7iTzIP_l1b5Y45i_Lo5sLG4VdA8n-8G612aF2n8Brq0La__9wkF3Wk8fY4r5OH9ep18TTQwVTGqpi8r1JWdUVXh6KrQ9FVLDr7J_4NOyGMpw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Borrell Puy, M ; Molto Valiente, C ; Vokinger, K ; Hwang, T ; Ocana Fernandez, A ; Templeton, A J ; Seruga, B ; Gich Saladich, I ; Barnadas, A ; Amir, E ; Tibau, A</creator><creatorcontrib>Borrell Puy, M ; Molto Valiente, C ; Vokinger, K ; Hwang, T ; Ocana Fernandez, A ; Templeton, A J ; Seruga, B ; Gich Saladich, I ; Barnadas, A ; Amir, E ; Tibau, A</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy297.007</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2018-10, Vol.29 (suppl_8)</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Borrell Puy, M</creatorcontrib><creatorcontrib>Molto Valiente, C</creatorcontrib><creatorcontrib>Vokinger, K</creatorcontrib><creatorcontrib>Hwang, T</creatorcontrib><creatorcontrib>Ocana Fernandez, A</creatorcontrib><creatorcontrib>Templeton, A J</creatorcontrib><creatorcontrib>Seruga, B</creatorcontrib><creatorcontrib>Gich Saladich, I</creatorcontrib><creatorcontrib>Barnadas, A</creatorcontrib><creatorcontrib>Amir, E</creatorcontrib><creatorcontrib>Tibau, A</creatorcontrib><title>1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkElPwzAQhcMmUZYfwG2ORaKt03Qhx6iLuERCAs6Ra0-CIR0bL5X673FoxYkLp5Fmvvfe6CXJXcqGKcuzESfSJEZbuR_n8yFj89Okl05n-eCRTdLzpMfycTaYT7PJZXLl3AdjbJaP897JWYSy52XJG1I-SARdg2gVKcFb2CBhrTwoAm8Vbx24YIy2XlEDby-w1loCJwlLGxoo5DbqnLfcK03QXy-Le-BCYItxhZE0xupd9O0X3SXqVsFqg5ygRKmEInRQNEhiD_1VGRmhSarOLYq23H7iTzIP_l1b5Y45i_Lo5sLG4VdA8n-8G612aF2n8Brq0La__9wkF3Wk8fY4r5OH9ep18TTQwVTGqpi8r1JWdUVXh6KrQ9FVLDr7J_4NOyGMpw</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Borrell Puy, M</creator><creator>Molto Valiente, C</creator><creator>Vokinger, K</creator><creator>Hwang, T</creator><creator>Ocana Fernandez, A</creator><creator>Templeton, A J</creator><creator>Seruga, B</creator><creator>Gich Saladich, I</creator><creator>Barnadas, A</creator><creator>Amir, E</creator><creator>Tibau, A</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20181001</creationdate><title>1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval</title><author>Borrell Puy, M ; Molto Valiente, C ; Vokinger, K ; Hwang, T ; Ocana Fernandez, A ; Templeton, A J ; Seruga, B ; Gich Saladich, I ; Barnadas, A ; Amir, E ; Tibau, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdy297_0073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borrell Puy, M</creatorcontrib><creatorcontrib>Molto Valiente, C</creatorcontrib><creatorcontrib>Vokinger, K</creatorcontrib><creatorcontrib>Hwang, T</creatorcontrib><creatorcontrib>Ocana Fernandez, A</creatorcontrib><creatorcontrib>Templeton, A J</creatorcontrib><creatorcontrib>Seruga, B</creatorcontrib><creatorcontrib>Gich Saladich, I</creatorcontrib><creatorcontrib>Barnadas, A</creatorcontrib><creatorcontrib>Amir, E</creatorcontrib><creatorcontrib>Tibau, A</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borrell Puy, M</au><au>Molto Valiente, C</au><au>Vokinger, K</au><au>Hwang, T</au><au>Ocana Fernandez, A</au><au>Templeton, A J</au><au>Seruga, B</au><au>Gich Saladich, I</au><au>Barnadas, A</au><au>Amir, E</au><au>Tibau, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval</atitle><jtitle>Annals of oncology</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>suppl_8</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdy297.007</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2018-10, Vol.29 (suppl_8)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdy297_007
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title 1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T14%3A11%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1563PDMagnitude%20of%20clinical%20benefit%20in%20trials%20supporting%20US%20Food%20and%20Drug%20Administration%20(FDA)%20accelerated%20approval%20(AA)%20and%20European%20Medicines%20Agency%20(EMA)%20conditional%20marketing%20authorisation%20(CMA)%20and%20subsequent%20trials%20supporting%20conversion%20to%20full%20approval&rft.jtitle=Annals%20of%20oncology&rft.au=Borrell%20Puy,%20M&rft.date=2018-10-01&rft.volume=29&rft.issue=suppl_8&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy297.007&rft_dat=%3Coup%3E10.1093/annonc/mdy297.007%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdy297.007&rfr_iscdi=true